CIDP Treatment at Home

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic immune-mediated disorder of the peripheral nerves. MedRx Infusion dispenses the intravenous and subcutaneous immune globulins FDA-approved for CIDP, delivers them with supplies at no charge, and can send a skilled nurse from an accredited nursing agency to administer them at home.

What is CIDP?

CIDP occurs when the immune system attacks myelin, the protective covering of the peripheral nerves. Its symptoms include progressive weakness and reduced sensation in the arms and legs. A neurologist's evaluation typically includes nerve conduction studies with electromyography (EMG). For how CIDP relates to Guillain-Barré syndrome, multifocal motor neuropathy and myasthenia gravis, see neuromuscular disorders.

MedRx Infusion Clinical Pharmacy is a home infusion and specialty pharmacy serving patients in 44 states, the District of Columbia and Puerto Rico. Therapy starts with a referral from the prescriber's office.

Treatments for CIDP that MedRx dispenses

The European Academy of Neurology and Peripheral Nerve Society guideline recommends intravenous immune globulin (IVIG) or corticosteroids as initial treatment, names plasma exchange as a further option, and recommends IVIG, subcutaneous immune globulin (SCIG) or corticosteroids for maintenance. The treating neurologist determines the therapy. Each product below is FDA-approved for adults with CIDP.

From IVIG to maintenance therapy

Immune globulin for CIDP is started intravenously. The prescriber sets the dose and the interval between infusions within the product's label, and reassesses the need for continued treatment. The Privigen label notes that, after an initial response, not all patients require indefinite maintenance therapy.

For maintenance, the prescriber may continue intravenous infusions or change to a subcutaneous immune globulin, which the patient or a caregiver gives at home after training. See subcutaneous immune globulin for CIDP.

Home, office or hospital

IVIG for CIDP is infused in hospital outpatient departments, in physicians' offices and at home; the prescriber's referral names the site of administration. At home, MedRx delivers the medication and supplies, and a nurse from an accredited nursing agency starts and manages the infusion and monitors vital signs and adverse reactions. IVIG at home describes the infusion day and the side effects of IVIG.

Some health plans apply a site-of-care policy to infused medicines, immune globulin among them: the first dose may be given at the provider's preferred site, and later doses move to a non-hospital setting unless a hospital setting is medically necessary. When a plan asks for that change, the prescriber's office can refer the patient to MedRx for infusion at home.

How home therapy starts

The neurologist's office sends a referral: for IVIG or SCIG, the Immunoglobulin Referral Form (PDF), with recent clinical notes, laboratory results and test reports, by fax, or a call. How to refer lists what to send.
MedRx's intake team verifies insurance benefits and obtains prior authorization when the plan requires it.
The prescriber specifies the product, or asks the MedRx pharmacist to select the brand.
Medication and supplies are delivered to the patient's door at no charge. Next-day delivery is available; timing varies by location.
A skilled, trusted and licensed nurse from an accredited nursing agency administers the infusion and monitors vital signs and adverse reactions; for SCIG, the nurse trains the patient or caregiver.
A MedRx pharmacist is available 24 hours a day, 7 days a week. MedRx's pharmacy team includes Ig Certified Pharmacists (IgCP), who hold a specialty certification in immune globulin therapy.

Insurance and cost

Health plans commonly require prior authorization for immune globulin. MedRx's intake team verifies coverage and works with the prescriber's office on the documentation before the first delivery. See insurance and prior authorization.

Medicare Part B covers IVIG given at home only for patients with a diagnosed primary immune deficiency disease, so that benefit does not apply to CIDP. For CIDP, Medicare's durable medical equipment policy covers subcutaneous immune globulin given at home through an infusion pump when the patient's CIDP has responded to IVIG and the treating practitioner determines that home administration is medically necessary and appropriate; its billing article lists Hizentra and HyQvia for CIDP. Medicare Advantage plans have their own prior authorization requirements, and each state runs its own Medicaid program. The intake team confirms coverage with the patient's plan before therapy starts.

Where out-of-pocket costs are a barrier, MedRx helps patients find and apply for copay assistance, grants and other financial aid. The manufacturers of these medicines also run patient support programs, named on each medication page.

Key facts

Organization: MedRx Infusion Clinical Pharmacy
What we do: A home infusion pharmacy and specialty pharmacy, with infusion nurses who visit patients at home and a pharmacist on call 24 hours a day, 7 days a week.
Where: Pharmacy at 417 N Oak St, Inglewood, CA 90302. Licensed in 44 states, the District of Columbia and Puerto Rico. See every place we serve
Accreditation: URAC (Specialty Pharmacy) and ACHC (Accreditation Commission for Health Care).
Phone, 24 hours: (844) 671-2600
Fax: (844) 671-2601

Accurate as of October 19, 2026

Questions about CIDP treatment at home

01Can IVIG for CIDP be given at home?

Yes, when the prescriber orders it for the home and the patient's health plan covers that setting. MedRx delivers the medication and supplies, and a skilled nurse from an accredited nursing agency administers the infusion and monitors the patient.

02Which immune globulin products are FDA-approved for CIDP?

Five are approved for intravenous use in adults with CIDP: Gammagard Liquid, Gamunex-C, Gammaked, Panzyga and Privigen. Two subcutaneous products, Hizentra and HyQvia, are approved as maintenance therapy to prevent relapse. MedRx dispenses all seven.

03Does Medicare cover IVIG at home for CIDP?

Medicare Part B's home IVIG benefit is for primary immune deficiency disease, not CIDP. For CIDP, Medicare's durable medical equipment policy covers subcutaneous immune globulin at home, Hizentra or HyQvia, when the patient has responded to IVIG. For IVIG, coverage depends on whether the medication falls under Part B or under the patient's Part D or Medicare Advantage plan. MedRx's intake team checks the patient's coverage before the first delivery.

04How long does immune globulin treatment for CIDP continue?

The prescriber decides, and reassesses it over time. The Gammagard Liquid and Privigen labels state that maintenance therapy has not been studied for longer than 6 months, and the Privigen label notes that not all patients require indefinite maintenance therapy. The Hizentra label says that maintenance therapy beyond the periods studied should be individualized to the patient's response and need for continued therapy.

05What other treatments are used for CIDP?

The European Academy of Neurology and Peripheral Nerve Society guideline names corticosteroids and plasma exchange besides immune globulin. Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), a subcutaneous FcRn blocker, is FDA-approved for adults with CIDP. The neurologist determines which therapy is appropriate.

06How does a neurology practice refer a CIDP patient to MedRx?

The practice sends the prescription and the Immunoglobulin Referral Form with recent clinical notes, laboratory results and test reports. MedRx's intake team then verifies benefits, obtains prior authorization where the plan requires it, and coordinates delivery and nursing. See how to refer, or use the online referral form.

07Can CIDP infusions move from a hospital to home?

Yes, if the prescriber orders home administration and the plan covers it. Some health plans ask for that change under a site-of-care policy. The prescriber's office sends MedRx a referral, and the intake team works with the office and the plan on the transition.